Ginkgo Bioworks  Inc. logo

Ginkgo Bioworks Inc.

DNA | NYSE
Chart Builder DCF Calculator
$7.98
+$0.10 (+1.27%)
At close: Sep 21, 2026, 4:00 PM ET
$7.90
-$0.08 (-1.00%)
Pre-market: Sep 22, 2026, 5:48 AM ET

Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Key Executives

Name Position
Jason Kelly Co-Founder, Co-COO, CEO & Director
Jennifer Wipf Co-Chief Operating Officer
Steven Coen Chief Financial Officer
Austin Che Co-Founder & Head of Strategy
Bartholomew Canton Co-Founder & CTO
Brian O'sullivan Head of Commercial
Daniel Marshall Senior Manager of Communications & Ownership
Karen Tepichin General Counsel & Secretary
Reshma Shetty Co-Founder, President & Director
Thomas Knight Jr. Founder

Latest SEC Filings

Date Type Title
Aug 25, 2026 4 Filing
Aug 06, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 4 Filing
Jul 30, 2026 8-K Current Report
Jul 30, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jul 20, 2026 4 Filing
Jun 15, 2026 4 Filing
View All SEC Filings
Ginkgo Bioworks Inc.
Ginkgo Bioworks  Inc. logo
Country United States
IPO Date Apr 18, 2021
Industry Biotechnology
Sector Healthcare
Employees 485
CEO Jason Kelly

Contact Details

27 Drydock Avenue Boston, Massachusetts 02210 United States

Stock Details

Ticker Symbol DNA
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001830214
CUSIP Number 37611X209
ISIN Number US37611X2099
SIC Code 2836

© 2026 bestshares.com. All rights reserved.